A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus
暂无分享,去创建一个
Alexander Staab | Remco de Bree | G. Giaccone | G. V. van Dongen | R. de Bree | C. Leemans | J. Buter | A. Staab | Giuseppe Giaccone | Jan Buter | Bernard M. Tijink | Guus A.M.S. van Dongen | M. Lang | C. René Leemans | Margreet S. Lang | B. Tijink | B. M. Tijink
[1] H. Koeppen,et al. Identification and immunotherapeutic targeting of antigens induced by chemotherapy , 2006, Nature Biotechnology.
[2] P. Hutchinson,et al. Toxic epidermal necrolysis: current evidence, practical management and future directions , 2005, The British journal of dermatology.
[3] R. Schilsky,et al. A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors , 2004, Clinical Cancer Research.
[4] W. Oyen,et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] A. Tolcher,et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Snow,et al. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] H. Oppelaar,et al. Comparison of aluminium (III) phthalocyanine tetrasulfonate‐ and meta‐tetrahydroxyphenylchlorin‐monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro , 2002, International journal of cancer.
[8] Jacques Ferlay,et al. Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.
[9] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[10] G. Snow,et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] G. Snow,et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] R. Phillips. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , 2000, Expert opinion on investigational drugs.
[13] N. Lawrence,et al. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle , 1998, Medicinal research reviews.
[14] R. Chari,et al. The development of antibody delivery systems to target cancer with highly potent maytansinoids. , 1997, Expert opinion on investigational drugs.
[15] K. Heider,et al. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas , 1996, Cancer Immunology, Immunotherapy.
[16] K. Heider,et al. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. , 1995, European journal of cancer.
[17] R. Brakenhoff,et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion , 1995, The Journal of cell biology.
[18] G. Snow,et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. , 1993, Cancer research.
[19] S. Takayama,et al. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. , 1993, Archives of otolaryngology--head & neck surgery.
[20] S. Shah,et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. , 1992, Cancer research.
[21] S. Taylor. Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.
[22] W. Lehmann,et al. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. , 1987, Archives of otolaryngology--head & neck surgery.
[23] B. Wessels,et al. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. , 1984, Medical physics.
[24] A. Meyers,et al. Distant metastases in head and neck epidermoid carcinoma , 1980, The Laryngoscope.
[25] J. Holland,et al. Phase I study of weekly maytansine given by iv bolus or 24-hour infusion. , 1979, Cancer treatment reports.
[26] J. Ingle,et al. Phase II evaluation of maytansine in patients with metastatic lung cancer. , 1978, Cancer treatment reports.
[27] R. Blum,et al. Maytansine: a phase I study of an ansa macrolide with antitumor activity. , 1978, Cancer treatment reports.
[28] J. Ingle,et al. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. , 1978, Journal of the National Cancer Institute.
[29] D. DuBois,et al. FIFTH PAPER THE MEASUREMENT OF THE SURFACE AREA OF MAN , 1915 .
[30] U. G. Dailey. Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.